These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35389071)

  • 1. Quantification of amyloid PET for future clinical use: a state-of-the-art review.
    Pemberton HG; Collij LE; Heeman F; Bollack A; Shekari M; Salvadó G; Alves IL; Garcia DV; Battle M; Buckley C; Stephens AW; Bullich S; Garibotto V; Barkhof F; Gispert JD; Farrar G;
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3508-3528. PubMed ID: 35389071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
    Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
    Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of amyloid PET using
    Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
    Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.
    Jovalekic A; Roé-Vellvé N; Koglin N; Quintana ML; Nelson A; Diemling M; Lilja J; Gómez-González JP; Doré V; Bourgeat P; Whittington A; Gunn R; Stephens AW; Bullich S
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3276-3289. PubMed ID: 37300571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Brain Amyloid Imaging.
    Krishnadas N; Villemagne VL; Doré V; Rowe CC
    Semin Nucl Med; 2021 May; 51(3):241-252. PubMed ID: 33482999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity.
    Ali DG; Bahrani AA; Barber JM; El Khouli RH; Gold BT; Harp JP; Jiang Y; Wilcock DM; Jicha GA
    J Alzheimers Dis; 2022; 88(3):1127-1135. PubMed ID: 35754276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Software compatibility analysis for quantitative measures of [
    Pemberton HG; Buckley C; Battle M; Bollack A; Patel V; Tomova P; Cooke D; Balhorn W; Hegedorn K; Lilja J; Brand C; Farrar G
    EJNMMI Res; 2023 May; 13(1):48. PubMed ID: 37225974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.
    Meyer PF; McSweeney M; Gonneaud J; Villeneuve S
    Prog Mol Biol Transl Sci; 2019; 165():63-106. PubMed ID: 31481172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
    Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomorgraphy imaging.
    Mohamed AZ; Nestor PJ; Cumming P; Nasrallah FA;
    J Neurol; 2022 Feb; 269(2):873-884. PubMed ID: 34191080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
    Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
    Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
    Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ;
    J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data.
    Iaccarino L; La Joie R; Koeppe R; Siegel BA; Hillner BE; Gatsonis C; Whitmer RA; Carrillo MC; Apgar C; Camacho MR; Nosheny R; Rabinovici GD;
    Neuroimage; 2022 Feb; 246():118775. PubMed ID: 34890793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.